国立研究開発法人国立がん研究センター東病院先端医療開発センター粒子線医学開発分野Division of Radiation Oncology and Particle Therapy, National Cancer Center Hospital East ◇ 277–0882 千葉県柏市柏の葉6–5−1 ◇ 6–5–1 Kashiwanoha, Kashiwa-shi, Chiba Pref. 277–0882, Japan
転移性去勢抵抗性前立腺癌に対する治療として，α線放出核種である塩化ラジウムが承認された。塩化ラジウムとプラセボの無作為第III相試験であるALSYMPCA studyで，関連事象の抑制効果に加えて生存率の向上が確認され，転移性去勢抵抗性前立腺癌における臨床的有用性が期待される。しかし，その至適使用方法確立には，未だ解決すべき課題があることを認識して，日常臨床で使用していくことが望まれる。
It is good news for us that radium dichloride which is an α emitter radionuclide was approved in Japan as a treatment option for the metastatic castration-resistant prostate cancer. Impairment of the quality of life due to the bone metastasis is a big problem, and you should avoid especially in patients with prostate cancer because natural history and progress of prostate cancer are relatively slow even if bone metastases occurs. In addition, the appearance of the therapeutic option that extends duration of survival in addition to the reduction of skeletal related event (SRE) has a positive impact on treatment modalities for castration resistance prostate cancer. As described, there is still the problems that should be resolved for the establishment of optimal usage of radium dichloride in management of castration resistance prostate cancer with bone metastasis.
Key words: α emitter; bone metastasis; radium chloride; castration resistant prostate cancer
© 2017 公益社団法人日本アイソトープ協会© 2017 Japan Radioisotope Association
This page was created on 2017-08-31T15:28:33.62+09:00
This page was last modified on 2017-12-07T17:57:36.372+09:00
このサイトは（株）国際文献社によって運用されています。
